JPMorgan's JPM Coin, launched on Ethereum for institutional clients, shows zero supply and transfers on the network days after its debut, according to a Sentora review. Meanwhile, JPMorgan Asset Management's tokenized liquidity fund JLTXX recorded $400 million in redemptions on Ethereum, coinciding with a rise to $450 million deployment on Solana, though no direct link between these moves was confirmed. The JPM Coin remains largely inactive on Ethereum, with no on-chain integration to JPMorgan's funds or DeFi protocols detected. This suggests JPMorgan's token initiatives are still in early stages on Ethereum, while its funds are expanding across multiple blockchains.
JPM Coin's zero supply on Ethereum contrasts with active market movements in major cryptocurrencies on Pluang. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 24, 2026 02:31 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell. Notable movers include COTI with a price of Rp202 and a 1-day change of +3.90%, VeChain (VET) at Rp130 with +3.33%, and Cosmos (ATOM) at Rp31,613 with +2.92%. Typical hold times range from 61 to 148 days, with varying buy/sell order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
